Active Substance: Ezetimibe.
Overview
Welcome to Dwaey, specifically on DIPLIM 10mg page.
This medicine contains an important and useful components, as it consists of
Ezetimibeis available in the market in concentration
Ezetimibe
Renal or mild hepatic impairment. Monitor LFTs. Immediately discontinue ezetimibe and any HMG-CoA reductase inhibitor or fibrate if myopathy is diagnosed or suspected. Exclude or treat secondary causes of dyslipidaemia prior to initiating therapy. Lactation: Excretion in milk unknown; use with caution
Hyperlipidaemias, Homozygous familial sitosterolaemia, Hypercholesterolaemia
Hypersensitivity; moderate to severe liver disease or unexplained serum transaminase elevation. Children <10 yr, lactation.
1-10% Diarrhea (4%),Upper respiratory tract symptoms (2-4%),Cough (2-4%),Pain in extremity (3%),Sinusitis (3%),Arthralgia (2-3%),Fatigue (2%),Influenza (2%),Increased liver transaminases (with HMG-CoA reductase inhibitors; >3 x ULN; 1%)
3
Ezetimibe localises at the brush border of the small intestine where it inhibits the absorption of cholesterol, thus decreasing its delivery to the liver. This results in decrease in cholesterol stores within the liver and an increase in cholesterol clearance from the blood.
Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.
Information not available